Related Experiment Video
Updated: Jul 26, 2026
07:42
Imaging of Estrogen Receptor-α in Rat Pial Arterioles using a Digital Immunofluorescent Microscope
Published on: November 29, 2011
Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree
1Reproductive Endocrinology Section, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
American Journal of Obstetrics and Gynecology
|April 17, 2001
Summary
Estrogens show cardiovascular benefits, while progestins may counteract them. Selective estrogen receptor modulators appear protective, impacting cardiovascular health.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Pharmacology
Background:
- Cardiovascular disease remains a leading cause of mortality.
- Hormone replacement therapy (HRT) and its cardiovascular implications are a significant area of research.
- Understanding the vascular effects of different hormonal agents is crucial for patient care.
Purpose of the Study:
- To review and synthesize the effects of estrogens, progestins, and selective estrogen receptor modulators (SERMs) on coronary and carotid arteries.
- To evaluate the potential impact of these agents on cardiovascular morbidity and mortality.
- To assess the clinical context of hormonal effects on vascular health.
Main Methods:
- Comprehensive literature review of English-language studies published between 1997 and 2000.
- Inclusion of in vitro, animal, human physiologic, and clinical trial studies.
- Synthesis and assessment of data, integrating in vivo human experience.
Main Results:
- Estrogens generally demonstrate favorable direct vascular effects.
- Progestins tend to oppose the beneficial effects of estrogens.
- Early evidence suggests selective estrogen receptor modulators (SERMs) may offer cardiovascular protection.
Conclusions:
- Hormonal therapy effects on cardiovascular health are complex and depend on the specific agent.
- Factors such as dosage, delivery route, and progestin type can modulate outcomes.
- Endothelial dysfunction assessment provides insight into hormone vascular properties, but clinical outcome correlations require further investigation.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...